Dr. Greiner's practice focuses on prosecution, opposition and litigation matters concerning German and European patents. With her experience in contentious proceedings, Elisabeth assists her clients ...

Eric Marandett, co-chair of Choate’s Intellectual Property Litigation Practice Group, represents biotech, pharmaceutical, and technology companies in high stakes patent litigation and other ...

Anita Spieth, co-chair of Choate’s IP Litigation Group, has more than 10 years of experience representing life sciences and technology companies in high stakes patent infringement, trade secrets, and ...

Jeff represents clients in patent litigation and other intellectual property issues, including some of the world's preeminent life sciences, pharmaceutical, biotech and high-tech companies. He has ...

Pauline Newman was appointed by President Ronald W. Reagan in 1984. From 1969 to 1984, Judge Newman served as Director, Patent, Trademark and Licensing Department, FMC Corporation, and as house ...

October is the scariest time of year. Young goblins walk the streets demanding treats, local haunted houses are packed full of fright-chasing teens, and the airwaves are filled with gore-splattered ...

A busy Monday brings all the highlights from BIO's Patient and Health Advocacy Summit last week, plus what BIO's talking about at the World Food Prize event in Iowa tomorrow. (793 words, 3 minutes, 57 ...

A special Friday edition with new data on 340B spending and a New York Times feature highlighting Pivot Bio's outstanding work to support farmers and the planet with biotech. (437 words, 2 minutes, 11 ...

WASHINGTON, DC (October 17, 2024 ) -- More than eight in ten voters believe that it's important for the National Institutes of Health to devote additional resources to understanding health conditions ...

Day 2 of the BIO Investor Forum in San Francisco brought the policy outlook and the market outlook (and much more) – here's what we learned. (395 words, 1 minute, 58 seconds) The Inflation Reduction ...

Day 1 of the BIO Investor Forum in San Francisco brought discussions on the fundraising environment and neurodegenerative disease targets and pipelines – we have recaps, plus more news to know today. ...

We’re heading to San Francisco for the BIO Investor Forum—you can follow the action all week long right here in your inbox and at Bio.News. Meanwhile, we look at how 340B could be improved and how ...